Search results for: Bernarda Zamora
Filter search results
OHE at ISPOR Washington DC (1): HTA, Evidence and Pricing
9 June 2016
…Can we operationalize it?” from Office of Health Economics Poster: Value of Transferability and Efficiency in HTA This poster was designed by Bernarda Zamora and presented by Grace Marsden. Value…
OHE Authors Develop a Supply and Demand Model of Pharmaceutical Markets to Set Cost-Effectiveness Thresholds to Maximise and Distribute Social Welfare
15 June 2020
…devices. American Economic Review, 103(1), 145-77. Berdud, M., Wallin-Bernhardsson, N., Zamora, B., Lindgren, P., and Towse, A (2019). The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and…
Cost-Effectiveness Thresholds and Expert Elicitation: a Bridge Too Far?
29 April 2021
…at: https://www.ohe.org/publications/critique-che-research-paper-81-methods-estimation-nice-cost-effectiveness-threshold [Accessed 28 Apr. 2021]. Cubi-Molla, P., Mott, D., Henderson, N., Zamora, B., Grobler, M. and Garau, M., 2021. Resource Allocation in Public Sector Programmes: Does the Value of…
Are Cost-Effectiveness Thresholds Fit for Purpose for Real-World Decision Making on Access to and Pricing of Pharmaceuticals? A New OHE Paper on Current Methods and Practices, and a Novel Approach for Optimal Thresholds
3 March 2020
…pricing and optimal level of cost-effectiveness threshold: a bargaining approach. OHE Consulting Report, London: Office of Health Economics. (forthcoming) Hernandez-Villafuerte, K., Zamora, B., Parkin, D., Devlin, N. and Towse,…
Exploring Variations in the Opportunity Cost Cost-effectiveness Threshold by Clinical Area: Results from a Feasibility Study in England
20 March 2019
…methods alone. The research was funded by the Association of the British Pharmaceutical Industry (ABPI). Hernandez-Villafuerte, K., Zamora, B., Feng, Y., Parkin, D., Devlin, N., Towse, A., 2019. Exploring Variations…
OHE Launches Discussion Paper and Consultation Exercise on Indication-based Pricing
10 May 2019
…Cole, A., Towse, A. and Zamora, B., 2019. Indication-Based Pricing (IBP) Discussion Paper . OHE Briefing, London: Office of Health Economics. Related research Mestre-Ferrandiz, J., Towse, A., Dellamano, R. and…
What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?
19 November 2024
…to believe that £15,000 per QALY is not a reliable estimate of the opportunity cost of spending. In fact, in an analysis of this estimate, Zamora and Towse (2023) identify several sets…
Assessing the Life-cycle Value of Second-generation Antipsychotics in Sweden and the UK
17 July 2019
… Citation Berdud, M., Wallin-Bernhardsson, N., Zamora, B., Lindgren, P., and Towse, A. (2019). Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in Sweden and the UK: The Case…
Payment Models for Multi-Indication Therapies
1 November 2021
…A., Zamora, B. (2020) Indication-Based Pricing (IBP) Consultation Report. OHE Consulting Report. Available from https://www.ohe.org/publications/indication-based-pricing-ibp-consultation-report. Neri, M., Towse, A. and Garau, M., 2018. Multi-Indication Pricing (MIP): Practical Solutions and Steps…